Abstract
Today the issues related to the management of patients with immunoinflammatory rheumatic diseases and the new coronavirus infection (NCI), despite numerous studies, remain open for discussion. Due to the rare occurrence of systemic lupus erythematosus (SLE), publications devoted to the study of the characteristics of the course of COVID-19 in this group of patients are limited to a description of a small series of cases. The article provides information on possible risk factors for severe NCI in patients with SLE. The article presents our own clinical observation of a patient with a long history of SLE who had bilateral pneumonia caused by SARS-CoV-2, against the background of low activity of the underlying disease, achieved by taking genetically engineered biologic drugs. NCI was accompanied by rapid progression of lung damage, prolonged persistence of fever, respiratory failure, and asthenic syndrome. Further monitoring of the patient’s condition is required.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
